170 related articles for article (PubMed ID: 2402772)
1. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation.
Piët MP; Chin S; Prince AM; Brotman B; Cundell AM; Horowitz B
Transfusion; 1990 Sep; 30(7):591-8. PubMed ID: 2402772
[TBL] [Abstract][Full Text] [Related]
2. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.
Prince AM; Horowitz B; Brotman B
Lancet; 1986 Mar; 1(8483):706-10. PubMed ID: 2870224
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations.
Horowitz B; Wiebe ME; Lippin A; Stryker MH
Transfusion; 1985; 25(6):516-22. PubMed ID: 3934801
[TBL] [Abstract][Full Text] [Related]
4. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma.
Horowitz B; Bonomo R; Prince AM; Chin SN; Brotman B; Shulman RW
Blood; 1992 Feb; 79(3):826-31. PubMed ID: 1310064
[TBL] [Abstract][Full Text] [Related]
5. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma.
Hellstern P; Sachse H; Schwinn H; Oberfrank K
Vox Sang; 1992; 63(3):178-85. PubMed ID: 1448962
[TBL] [Abstract][Full Text] [Related]
6. Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives.
Edwards CA; Piet MP; Chin S; Horowitz B
Vox Sang; 1987; 52(1-2):53-9. PubMed ID: 3111089
[TBL] [Abstract][Full Text] [Related]
7. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
8. Enhancement in the safety of immune globulins prepared from high-risk plasma.
Gao F; Prince AM; Pascual D; Horowitz B
Vox Sang; 1993; 64(4):204-9. PubMed ID: 8390765
[TBL] [Abstract][Full Text] [Related]
9. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products.
Roberts P
Biologicals; 2000 Mar; 28(1):29-32. PubMed ID: 10799053
[TBL] [Abstract][Full Text] [Related]
10. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
[TBL] [Abstract][Full Text] [Related]
11. A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Transfusion; 2006 Dec; 46(12):2100-8. PubMed ID: 17176321
[TBL] [Abstract][Full Text] [Related]
12. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.
Dichtelmüller HO; Biesert L; Fabbrizzi F; Gajardo R; Gröner A; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Pifat D; Osheroff W; Poelsler G
Transfusion; 2009 Sep; 49(9):1931-43. PubMed ID: 19497061
[TBL] [Abstract][Full Text] [Related]
13. Comparable virus inactivation by bovine or vegetable derived Tween 80 during solvent/detergent treatment.
Seitz H; Blümel J; Schmidt I; Willkommen H; Löwer J
Biologicals; 2002 Sep; 30(3):197-205. PubMed ID: 12217344
[TBL] [Abstract][Full Text] [Related]
14. [Virus inactivated plasma].
Köhler M; Wieding JU
Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():73-6. PubMed ID: 8000259
[TBL] [Abstract][Full Text] [Related]
15. Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate.
Burnouf T; Chou ML; Cheng LH; Li ZR; Wu YW; El-Ekiaby M; Tsai KH
Vox Sang; 2013 Jan; 104(1):1-6. PubMed ID: 22758375
[TBL] [Abstract][Full Text] [Related]
16. Virus safety of solvent/detergent-treated antihaemophilic factor concentrate.
Horowitz MS; Rooks C; Horowitz B; Hilgartner MW
Lancet; 1988 Jul; 2(8604):186-9. PubMed ID: 2899662
[TBL] [Abstract][Full Text] [Related]
17. Single-use technology for solvent/detergent virus inactivation of industrial plasma products.
Hsieh YT; Mullin L; Greenhalgh P; Cunningham M; Goodrich E; Shea J; Youssef E; Burnouf T
Transfusion; 2016 Jun; 56(6):1384-93. PubMed ID: 27125447
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of lipid-enveloped viruses in labile blood derivatives by unsaturated fatty acids.
Horowitz B; Piët MP; Prince AM; Edwards CA; Lippin A; Walakovits LA
Vox Sang; 1988; 54(1):14-20. PubMed ID: 2831669
[TBL] [Abstract][Full Text] [Related]
20. Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Biologicals; 2007 Oct; 35(4):349-53. PubMed ID: 17656111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
